Still too risky to buy back in. Two catalysts left really... (Full year report). - has the cash burn stopped? Hows the UK business doing? and (Debt to Equity Swap) - what will the end result to existing shareholders be?
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
